Janux Therapeutics, Inc.
JANX
$23.64
$0.632.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -97.10% | 28.12% | 30.99% | 54.12% | 94.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -97.10% | 28.12% | 30.99% | 54.12% | 94.86% |
| Cost of Revenue | 68.77% | 21.36% | -2.61% | -22.70% | -36.29% |
| Gross Profit | -177.50% | -20.29% | 8.41% | 35.80% | 55.79% |
| SG&A Expenses | 65.17% | 61.17% | 57.03% | 53.92% | 11.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.27% | 53.37% | 35.00% | 18.47% | -4.72% |
| Operating Income | -119.74% | -55.89% | -35.45% | -14.45% | 14.72% |
| Income Before Tax | -139.85% | -39.84% | -18.36% | 3.30% | 34.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -139.85% | -39.84% | -18.36% | 3.30% | 34.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -139.85% | -39.84% | -18.36% | 3.30% | 34.97% |
| EBIT | -119.74% | -55.89% | -35.45% | -14.45% | 14.72% |
| EBITDA | -123.60% | -57.48% | -36.27% | -14.47% | 15.68% |
| EPS Basic | -96.30% | -11.00% | 4.61% | 20.33% | 43.67% |
| Normalized Basic EPS | -96.28% | -11.00% | 4.62% | 20.34% | 43.67% |
| EPS Diluted | -96.30% | -11.00% | 4.61% | 20.33% | 43.67% |
| Normalized Diluted EPS | -96.28% | -11.00% | 4.62% | 20.34% | 43.67% |
| Average Basic Shares Outstanding | 20.04% | 24.24% | 22.14% | 19.85% | 17.50% |
| Average Diluted Shares Outstanding | 20.04% | 24.24% | 22.14% | 19.85% | 17.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |